Patients With Resected Stage II Colon Cancer
Conditions
Brief summary
The objective of CIRCULATE trial is to improve care of patients after colon tumor surgery, based on an innovative marker: circulating tumor DNA.
Interventions
DRUGmFOLFOX6
Patients receive adjuvant chemotherapy every 2 weeks during 6 months: FOLFOX6m (5-FU, leucovorin and oxaliplatin).
Sponsors
Centre Hospitalier Universitaire Dijon
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Signed written informed consent obtained prior to any study specific procedures * Age ≥ 18 years and ≤ 75 years * Histologically confirmed stage II colon and high rectum adenocarcinoma excluding low and medium rectal cancers (tumor location ≥ 12 cm from the anal verge by endoscopy and/or above the peritoneal reflection at surgery are still eligible), without gross or microscopic evidence of residual disease after surgery with curative intent. Pathology report must be faxed to CRGA just after patient's randomization. * At least 12 lymph nodes analyzed * Patient with MSI + tumors can be included * All patients must have been discussed in multidisciplinary meetings with a decision of not performing adjuvant chemotherapy * No metastatic disease on CT-Scan and/or liver MRI done within 3 months before randomization. * Randomization planned up to 7 weeks after curative R0 resection * WHO performance Status \< 2 * No prior chemotherapy for colo-rectal cancer * No prior abdominal or pelvic irradiation for colo-rectal cancer * Life expectancy of ≥ 5 years * Adequate haematological function: with neutrophils ≥ 1,500 /mm3, platelet count ≥ 100,000/mm3, hemoglobin ≥ 9 g/dL (5,6 mmol/l) * Total bilirubin ≤ 1.5 x ULN (upper limit of normal) * ASAT and ALAT ≤ 2.5 x ULN * Alkaline phosphatase ≤ 2.5 x ULN * Serum creatinine ≤ 120 µmol/L or creatinine clearance ≥50 ml/min according MDRD (Modification of Diet in Renal Disease) * Carcinoembryogenic antigen (CEA) ≤ 1.5 x ULN after surgery (during screening period) * Negative pregnancy test for registration(for women of childbearing age) * Patient affiliated to a social security system
Exclusion criteria
* T4b tumors * Peripheral neuropathy \> grade 1 * Comorbidity influencing the 5 year patients' survival including clinically relevant cardiovascular disease, * Ischemic myocardial infarction in the last year and/or unstable ischemic cardiopathy, * Participation to another interventional study for postoperative therapy * Partial or complete DPD deficiency * Legal incapacity or physical, psychological social or geographical status interfering with the patient's ability to sign the informed consent or to finish the study * Medical history of other concomitant or previous malignant disease, except adequately treated in situ carcinoma of the uterine cervix, basal or squamous cell carcinoma of the skin, or cancer in complete remission for ≥ 5 years, * Lack of effective contraception in patients (men and/or women) of childbearing age, pregnant or breastfeeding women. Women of childbearing potential should agree to use a method of contraception during treatment of the trial and at least 4 months after discontinuation of oxaliplatin therapy and at least 30 days after discontinuation of 5-fluorouracil. Men must agree to use a method of contraception during treatment and at least 6 months after stopping oxaliplatin therapy and at least 3 months after stopping 5-fluorouracil.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year Disease-Free Survival in ctDNA positive patients | 3-years |
Countries
France
Contacts
CONTACTJulien TAIEB
Outcome results
None listed